Deborah T. Gold
Professor Emeritus in Psychiatry and Behavioral Sciences
In particular, my current research focuses on compliance and persistence with osteoporosis medications. One current study focuses on the impact of race/ethnicity on medication decision making. We are trying to determine the relative weight of cost, convenience, dosing interval, efficacy, and safety in making medication decisions and taking medication on a regular basis as prescribed by a health care provider. I am also on the Steering Committees of two major observational studies with different osteoporosis medications.
Finally, I have worked with voluntary health organizations to translate our research findings into positive real-world outcomes for people with chronic illness. I serve on the Board of Trustees of the National Osteoporosis Foundation and am Chair of its Education Committee. I have also chaired the International Symposium on Osteoporosis (ISO) for the last 8 years.
Gold, Deborah T., and Stuart L. Silverman. “Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?” Curr Osteoporos Rep, vol. 5, no. 1, Mar. 2007, pp. 3–7. Pubmed, doi:10.1007/BF02938616. Full Text
Gold, Deborah T., et al. “A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.” Curr Med Res Opin, vol. 23, no. 3, Mar. 2007, pp. 585–94. Pubmed, doi:10.1185/030079906X167615. Full Text
Keen, Richard, et al. “European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.” Curr Med Res Opin, vol. 22, no. 12, Dec. 2006, pp. 2375–81. Pubmed, doi:10.1185/030079906X154079. Full Text
Gold, Deborah T., et al. “Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.” Curr Med Res Opin, vol. 22, no. 12, Dec. 2006, pp. 2383–91. Pubmed, doi:10.1185/030079906X154042. Full Text
Gold, Deborah T., and Samantha Solimeo. “Osteoporosis and depression: a historical perspective.” Curr Osteoporos Rep, vol. 4, no. 4, Dec. 2006, pp. 134–39. Pubmed, doi:10.1007/s11914-996-0021-6. Full Text
Gold, Deborah T., et al. “How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.” Ann Pharmacother, vol. 40, no. 6, June 2006, pp. 1143–50. Pubmed, doi:10.1345/aph.1G534. Full Text
Weiss, Thomas W., et al. “An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study.” Curr Med Res Opin, vol. 22, no. 5, May 2006, pp. 949–60. Pubmed, doi:10.1185/030079906X104740. Full Text
Weber, T. J., and D. T. Gold. “Update on male osteoporosis.” Advanced Studies in Medicine, vol. 6, no. 4, Apr. 2006, pp. 171–81.
Gold, Deborah T., et al. “Initial experience with teriparatide in the United States.” Curr Med Res Opin, vol. 22, no. 4, Apr. 2006, pp. 703–08. Pubmed, doi:10.1185/030079906X100159. Full Text
Gold, Deborah T., and Betsy McClung. “Approaches to patient education: emphasizing the long-term value of compliance and persistence.” Am J Med, vol. 119, no. 4 Suppl 1, Apr. 2006, pp. S32–37. Pubmed, doi:10.1016/j.amjmed.2005.12.021. Full Text